SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions

Stage IV Non-small Cell Lung Cancer

Interventions

RADIATION

SBRT+Osimertinib

Received SBRT after three months of Osimertinib treatment

DRUG

Osimertinib 80 MG

Osimertinib 80mg, po, Qd

Trial Locations (1)

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, Hubei, P. R. China, Wuhan

All Listed Sponsors

collaborator

Hubei Cancer Hospital

OTHER

lead

Li Zhang

OTHER

NCT05583409 - SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC | Biotech Hunter | Biotech Hunter